DBV Technologies (NasdaqCM:DBVT) 2026 Conference Transcript

Summary of DBV Technologies Conference Call Company Overview - Company: DBV Technologies - Industry: Biotechnology, specifically focused on food allergies - Product: Viaskin, a platform for epicutaneous immunotherapy targeting food allergies, primarily peanut allergy [4][5] Core Points and Arguments - Market Need: Food allergies, particularly peanut allergies, represent a significant unmet medical need with high healthcare costs and life-threatening reactions. 80% of patients do not outgrow peanut allergies [4][5] - Regulatory Path: DBV plans to submit two Biologics License Applications (BLAs) in 2026: one for children aged 4-7 and another for 1-3 years old. The first submission is expected in the first half of 2026 [5][9][10] - Clinical Data: Over 1,600 patients have been treated with Viaskin Peanut, showing a 47% responder rate in the active arm compared to 15% in placebo during the VITESSE study. The treatment effect improves over time, with ongoing studies showing positive results [20][21][35] - Safety Profile: The treatment has a low anaphylaxis rate of 0.5%, with mild to moderate local site reactions that typically resolve within months [35] Development Strategy - Age Group Focus: The separation of BLAs for different age groups is seen as advantageous, allowing for two distinct market opportunities. The company emphasizes the importance of early treatment for better desensitization outcomes [8][10] - Clinical Milestones: A rich agenda of clinical milestones is planned over the next 18 months, including BLA submissions and study completions [9][10] Market Dynamics - Prevalence: Approximately 670,000 children aged 1-7 are affected by peanut allergies, with only 20% expected to outgrow them. The majority are currently managing their allergies through avoidance and epinephrine use [41][43] - Competitive Landscape: The launch of Xolair has increased interest in food allergies, but DBV's approach is differentiated as it focuses on desensitization rather than IgE suppression [46][48] Future Pipeline - Next Product: Following Viaskin Peanut, DBV plans to develop a treatment for cow's milk protein allergies, which is also a significant opportunity in the market [80][81] Financial Considerations - Funding: DBV has EUR 300 million in cash, sufficient to fund operations through the launch of the 4-7 year old product. The company is focused on building a commercial team and inventory for the launch [89][90] Communication Strategy - Target Audience: The company plans to educate both parents and allergists about the benefits of Viaskin, emphasizing risk reduction and the potential for improved quality of life for children with food allergies [25][26][41] Conclusion DBV Technologies is positioned to address a significant unmet need in the food allergy market with its innovative Viaskin platform. The company is on track for regulatory submissions and has a clear strategy for market entry and future product development.